MicroRNA Market Size, Share, Opportunities, And Trends By Type (Products, Services), By Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, Others), By End-Use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Other End-users), And By Geography - Forecasts From 2023 To 2028

The global microRNA market was valued at US$1410.532 million in 2021 and is expected to grow at a CAGR of 18.19% during the forecast period.

Small non-coding RNA molecules known as microRNAs (miRNAs) play a critical function in the control of gene expression in a range of organisms. It is normally made up of 21 to 25 nucleotides and is a single-stranded RNA molecule. The increasing number of clinical trials for various diseases focusing on microRNA along with the rising cases of chronic illnesses such as cancer is a major growth driver in the microRNA market. Moreover, the increasing shift towards personalized medicine coupled with technological developments and launches by the market players are further contemplated to augment the microRNA market growth.

Increasing Clinical Trials of MicroRNA

The molecular and cellular roles of microRNA have been identified since their discovery. The first proof of microRNAs' involvement in human disease was published in 2002 and after that numerous studies have been conducted on the relevance of microRNA in humans as well as other organisms thereby boosting the microRNA market. For instance, a recent study titled microRNAs in the Diagnosis of atherosclerotic plaque instability was started in September 2022 by Moscow State Medical University and it is estimated to be complete by August 2024. Finding biomarkers of unstable atherosclerosis in the brachiocephalic arteries is the goal of the research.

Rising Prevalence of Cancer

The demand for efficient diagnostic and therapeutic technologies is being driven by the increasing incidence of cancer. MicroRNAs offer chances for better illness management and individualized treatments due to their participation in disease processes and potential as biomarkers or therapeutic targets. Therefore, the rising cancer cases are a major growth factor in the microRNA market. For instance, nearly 10 million deaths, or one in six deaths, were caused by cancer in 2020, making it the top cause of mortality worldwide as per the WHO data. Moreover, 400 000 kids are diagnosed with cancer in children every year according to the WHO report.

Growing Focus on Personalized Medicine

The idea of personalized medicine, which tries to customize medical interventions for specific patients, has drawn a lot of interest. Because of their capacity to reflect both disease states and individual differences, microRNAs are potential targets for personalized treatment thereby propelling the microRNA market. The development of individualized treatment plans is aided by the capacity to examine miRNA expression profiles and create miRNA-based therapeutics. According to the American Cancer Society, in cases where a patient's chance of developing a particular cancer is higher, precision medicine may be applied. For instance, a patient might learn that cancer runs in their family, for instance, or a doctor might see a pattern of cancer in the patient's family. 

Opportunities in the MicroRNA market

The growth factors mentioned above provide an immense expansion opportunity for the microRNA market. Moreover, other factors are also offering entrance opportunities into the microRNA market. For example, microRNAs are being researched for possible applications. These include disciplines like veterinary medicine, agriculture, and environmental monitoring. Research, product development, and commercialization potential are expanded as a result of studying the function of microRNAs in various sectors.  Additionally, the funding and investments received by the companies involved in the microRNA further extend the growth opportunity thereby propelling the microRNA market. For instance, InteRNA Technologies received a total of € 18.5 million in a series B financing round held in September 2021. This money was utilized to advance the clinical assessment of the microRNA lead candidate INT 0-1B3 in patients with solid tumors that were progressed.

Restraints in the Market

There are a few factors that are expected to limit the microRNA market. The creation of efficient diagnostic and therapeutic approaches may be hampered by a lack of a thorough understanding of miRNA biology. It is difficult to translate microRNA research into therapeutically useful uses. Rigorous clinical trials and extensive research are needed to validate the diagnostic or therapeutic value of miRNAs. It takes time, money, and proof of clinical utility to complete complex processes including clinical validation, regulatory approval, and incorporation into standard clinical practice. Moreover, efficient delivery of microRNA-based therapies to target tissues or cells is a major challenge because miRNAs are often fragile and can be swiftly destroyed in vivo.

North America is Projected to Grow Significantly

The North American region is estimated to hold a significant share of the microRNA market. Various factors attributed to such a share are favorable regulatory policies, the growing burden of chronic diseases such as cancer, and chronic kidney disease, and increasing scientific research studies. For instance, CDC estimated that 35.5 million US adults which equates to 14% of the population, were having CKD in 2022. According to the United States Renal Data System (USRDS), there were more than 750,000 people in the US who had ESRD in 2019. Additionally, the presence of major market leaders such as Thermo Fisher Scientific and BioGenex further accelerates the microRNA market in the region.

MicroRNA Market Players

• Horizon Discovery Ltd is a biotechnology business with its headquarters in the UK,  It focuses on the use of gene editing and gene modulation technologies to hasten the discovery, development, and production of novel medications, treatments, and cell-based research tools. Horizon Discovery provides CRISPR-Cas9-based gene editing tools such as guide RNA libraries, knockout cell lines, and specialized cell line engineering services.
• BioGenex specializes in automated systems and molecular pathology solutions for cancer research and cancer diagnostics. Chromogenic ISH (CISH) and fluorescence ISH (FISH) tests, which enable the identification and localization of certain nucleic acid targets inside tissue samples, are two of the wide variety of ISH solutions offered by BioGenex.
• QIAGEN is one of the leading global medical companies with a focus on sample and assay technologies for molecular diagnostics, applied testing, scholarly research, and pharmaceutical studies. QIAGEN creates and sells a variety of diagnostic platforms and assays for the diagnosis of genetic abnormalities, oncology-related mutations, infectious diseases, and other therapeutic applications.

Key Market Developments

• In September 2022, Craif launched a breast cancer test as a part of the miSignal® series. This test enables early-stage cancer detection using urinary microRNA. This new breast cancer test can detect two types of cancer (breast and ovary) at once.
• In July 2022, MiRXES launched the world’s first research project for a multi-cancer screening test titled CADENCE. The project aimed to develop a multi-cancer early detection test for up to nine cancers including breast, and liver. It was focused to discover and validate novel combinations of blood-borne microRNA and DNA biomarkers for multi-cancer tests.

MicroRNA Market Scope:

Segmentation:

• By Type
  • Products
  • Services
• By Application
  • Cancer
  • Infectious Diseases
  • Immunological Disorder
  • Cardiovascular Disease
  • Neurological Disease
  • Others
• By End-Use
  • Biotechnology & Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Other end-users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others